1	Building resilient cervical cancer prevention through gender-neutral HPV vaccination
2	
3	Irene Man <sup>1</sup> , Damien Georges <sup>1</sup> , Rengaswamy Sankaranarayanan <sup>2</sup> , Partha Basu <sup>1</sup> , Iacopo Baussano <sup>1*</sup>
4	
5	1. Early Detection, Prevention and Infections Branch, International Agency for Research on
6	Cancer (IARC/WHO), Lyon, France
7	2. Karkinos Healthcare, Ernakulam - 682 017, India
8	
9	*Address for correspondence: Dr Iacopo Baussano, International Agency for Research on Cancer
10	(IARC/WHO), 25, avenue Tony Garnier, CS 90627, 69366 Lyon Cedex 07, France; Tel.: +33-
11	472738048; Email: <u>baussanoi@iarc.who.int</u>
12	
13	Running title: Resilience through gender-neutral HPV vaccination
14	Main text word count: 3619
15	Abstract word count: 198 (max 200)
16	Number of references: 38
17	Tables: 1

18 Figures: 4

#### 19 ABSTRACT (max. 200 words)

20 The COVID-19 pandemic has disrupted HPV vaccination programmes worldwide. Using an 21 agent-based model, EpiMetHeos, recently calibrated to Indian data, we illustrate how shifting 22 from girls-only (GO) to gender-neutral (GN) vaccination strategy could improve the resilience of 23 cervical cancer prevention against disruption of HPV vaccination. In the base case of 5-year 24 disruption with no coverage, shifting from GO to GN strategy under 60% coverage (before 25 disruption) would increase the resilience, in terms of cervical cancer cases still prevented in the 26 disrupted birth cohorts per 100,000 girls born, by 2.8-fold from 107 to 302 cases, and by 2.2-fold 27 from 209 to 464 cases under 90% coverage. Furthermore, shifting to GN vaccination helped in 28 reaching the WHO elimination threshold. Under GO vaccination with 60% coverage, the age-29 standardised incidence rate (ASIR) of cervical cancer in India in the long-term with vaccination 30 decreased from 11.0 to 4.7 cases per 100,000 woman-years (above threshold), as compared to 31 2.8 cases (below threshold) under GN with 60% coverage and 2.4 cases (below threshold) under 32 GN with 90% coverage. In conclusion, GN HPV vaccination is an effective strategy to improve 33 the resilience to disruption of cancer prevention programmes and to enhance the progress 34 towards cervical cancer elimination.

#### **35 INTRODUCTION**

In August 2020, the World Health Assembly adopted the Global Strategy for cervical cancer 36 37 elimination, with the overarching target of reducing the age-standardised incidence rate (ASIR) of 38 cervical cancer to fewer than four cases per 100,000 woman-years (WHO, 2020b). To reach this 39 target, the following actions have been recommended: to fully vaccinate 90% of all girls with the 40 HPV vaccine by age 15 years, to screen 70% of women using a high-performance test by the age 41 of 35, and again by the age of 45, and to treat 90% of women with pre-cancer and 90% of women 42 with invasive cancer (WHO, 2020b). However, the delivery of these interventions has been 43 severely disrupted worldwide by the outbreak of the COVID-19 pandemic, which was declared a 44 global emergency in the same year by the World Health Organization (WHO) (WHO, 2020a). 45 More specifically, HPV vaccination worldwide was affected at many different levels: a) where 46 population-based HPV vaccination programmes were already active, vaccine delivery slowed 47 down or was interrupted (Muhoza et al., 2021), b) the launch of HPV vaccination programmes was 48 delayed in several countries, in particular in resource-limited settings (The Lancet, 2022), and c) 49 the production of HPV vaccines was also limited to favour the manufacturing of other vaccines 50 (WHO, 2022a).

Apart from the COVID-19 pandemic, which has resulted in extensive disruption of healthcare provision at a global level, health-care systems or public-health programmes at a local level have also regularly suffered severe disruption caused by other factors such as changes in political commitment, financial constraints, scepticism of the civil society, geo-political unrest, and environmental disasters (Colón-López et al., 2021; Gallagher et al., 2017; Germani, März, Clarinval, & Biller-Andorno, 2022; Jawad, Hone, Vamos, Cetorelli, & Millett, 2021; Larson, 2020; McGrath, 2022). Such circumstances may even lead key public health actors to reconsider their previous commitments. These partial or complete disruptions of organised disease prevention and control programmes may multiply public health crises (Sharpless, 2020), as well as provoking substantial, usually unquantified waste of human, logistic, and financial resources (Richards, Anderson, Carter, Ebert, & Mossialos, 2020). Clearly, devising and implementing pre-emptive measures aimed at improving the resilience of public health programmes would help mitigate disruption.

64 In a previous study, conducted before the COVID-19 pandemic in a high-income country, 65 we showed that the addition of vaccination in boys to a programme targeting girls only could 66 increase the resilience of the vaccination programme (Elfstrom, Lazzarato, Franceschi, Dillner, & 67 Baussano, 2016). In the present paper, we complement our previous work by assessing the potential effect of gender-neutral HPV vaccination on resilience and progress towards the 68 69 elimination of cervical cancer in India, and this in the country context where the prospect of 70 introducing HPV vaccination into the national immunisation programme (NIP) has significantly 71 improved following the recent marketing authorisation granted to an indigenous vaccine (The 72 Lancet, 2022).

#### 73 MATERIALS AND METHODS

74 <u>Model</u>

To estimate the impact of HPV vaccination on cervical cancer burden, we used the agent-based HPV transmission model, EpiMetHeos (Man, Georges, de Carvalho, et al., 2022), in combination with the cervical cancer progression model, Atlas (Bonjour et al., 2021). EpiMetHeos was used to simulate the dynamic sexual contact network through which HPV infections were transmitted and hence derive the impact of vaccination on incidence of high-risk HPV types. Based on the impact on HPV incidence, Atlas was then used to derive the impact on cervical cancer burden.

81 The models were previously calibrated to sexual behaviour, HPV prevalence, cervical 82 cancer incidence in India (Man, Georges, de Carvalho, et al., 2022). Since the high-quality data on 83 HPV prevalence and cervical cancer incidence data needed to calibrate the models to each Indian 84 state were not available, we used a Footprinting framework to approximate the missing data and 85 extrapolate the impact by state. In short, we first identified clusters of states with similar patterns 86 of cervical cancer incidence. We then calibrated EpiMetHeos to the state of Tamil Nadu to 87 represent the states in the high cancer incidence cluster, and the state of West Bengal to represent 88 the states in the low cancer incidence cluster, using the available sexual behaviour and HPV 89 prevalence data of these two states. Finally, we estimated the impacts for Tamil Nadu and West 90 Bengal and extrapolated these to other states within each cluster. More details on model calibration 91 can be found in previous publications (Man, Georges, Bonjour, & Baussano, 2022; Man, Georges, 92 de Carvalho, et al., 2022) and in Appendices A.1-3. This study adheres to HPV-FRAME, a quality 93 framework for modelled evaluations of HPV-related cancer control (Appendix A.4) (Canfell et al., 94 2019).

95

## 96 <u>Simulation scenarios</u>

97 Coinciding with the recent development of a locally produced quadrivalent HPV vaccine in India 98 (The Lancet, 2022), we simulated vaccination with a quadrivalent vaccine targeting two high-risk 99 types, HPV16 and HPV18 (and two low-risk types, HPV6 and HPV11). As the marketing 100 authorisation awarded to the locally produced vaccine was based on successful immune-bridging between the new vaccine and the existing quadrivalent vaccine (Gardasil<sup>TM</sup>, MSD), we based our 101 102 model assumptions on the efficacy estimates of the IARC India vaccine trial, which considered 103 Gardasil (Basu et al., 2021; Joshi et al., 2022). In this trial, no difference was found between the 104 efficacy estimates of the single-dose and two-dose schedules, which were moreover stable after up 105 to 10 years follow-up. Hence, we based the model on pooled efficacy estimates (95% efficacy for HPV16 and HPV18, 9% cross-protection for HPV 31, HPV33, and HPV45, and 0% efficacy for 106 107 the remaining high-risk HPV types) and assumed no waning of vaccine immunity over time. In 108 doing so, the modelled efficacy could represent vaccination under either a single-dose or two-dose 109 schedule.

Routine HPV vaccination at age 10 under the girls-only (GO) or gender-neutral (GN) strategy was modelled with different vaccination coverages in boys and girls from the range between 0% to 100%, at 10% intervals. To consider the impact of scaling up vaccination from suboptimal coverage in girls, we highlighted the following four scenarios: A) GO strategy with 60% coverage in girls, B) GO strategy with 90% coverage in girls, C) GN strategy with 60% coverage in both girls and boys, D) GN strategy with 90% coverage in both girls and boys.

To assess the resilience of different vaccination strategies on cervical cancer prevention, we simulated the above scenarios first without disruption of the HPV vaccination programme, and then with disruption occurring 10 years after the start of vaccination. As the base case, we simulated a disruption period of 5 years with total interruption of HPV vaccine delivery, i.e., 0% vaccination coverage in both boys and girls. As sensitivity analyses, we considered less strong disruption with still 20% and 40 % vaccination coverage in girls (but still 0% in boys), as well as shorter or longer durations of disruption of 1, 2, and 10 years, and no restart of vaccination. These sensitivity analyses were considered to represent different types of disruption attributable to a COVID-19 pandemic or to any other interference of the HPV vaccination programme.

125

## 126 <u>Model outcomes</u>

Life-time number of cervical cancer cases prevented per 100,000 girls born was derived for the first 40 birth cohorts following the introduction of vaccination. Specifically, the mean number of cases still prevented across the birth cohorts with disruption, as a result of previous HPV vaccination, was defined as a measure of resilience, which was compared to the mean number of cases prevented across the birth cohorts before the disruption.

To assess progress towards cervical cancer elimination, we also derived the agestandardised incidence rate (ASIR) of cervical cancer up to 100 years after the start of vaccination. The long-term impact of vaccination was defined as the impact at 100 years after the start of vaccination. The Segi world standard population was used for the standardisation (Segi, 1960). Model-estimates of ASIR were compared to the threshold for elimination defined by the WHO of 4 cases per 100,000 woman-years (WHO, 2020b).

Model outcomes were reported as the mean and the 10th and 90th percentiles, i.e., uncertainty interval (UI), of the simulations using the 100 parameter sets best fitting the sexual behaviour and HPV prevalence data obtained through calibration.

- 141 Given the extremely low coverage of the existing screening programme in India, we have
- 142 not considered the impact of screening in our study (Bruni et al., 2022).

143

## 144 **RESULTS**

145 *Gender-neutral vaccination to improve resilience of cervical cancer prevention* 

As the base case, we simulated disruption in vaccination for 5 years, taking place 10 years after the introduction of vaccination. Life-time cervical cancer cases prevented in the birth cohorts vaccinated prior to the disruption period ranged between 562 (UI: 444, 676) and 807 (UI: 752, 853) cases per 100,000 girls born in the four highlighted scenarios. The highest impact was achieved by the GN strategy with 90% coverage, closely followed by GO with 90% coverage, then GN with 60% coverage, and then GO with 60% coverage (Figure 1).

152 Among the four highlighted scenarios, the GO strategy with 60% coverage was also the 153 least resilient (Figure 1). We found that the life-time number of cervical cancer cases prevented 154 would drop considerably from 562 (UI: 444, 676) cases in the undisrupted cohorts to 107 (UI: 7, 155 214) cases per 100,000 girls born in the disrupted cohorts (i.e., resilience of 107). Increasing the 156 coverage under the GO strategy from 60% to 90% would lead to a small absolute gain in resilience, 157 from 107 (UI: 7, 214) to 209 (UI: 81, 340) cases prevented per 100,000 girls born, and this despite 158 the larger increase in impact in the undisrupted cohorts vaccinated prior to the disruption from 562 159 (UI: 444, 676) to 773 (UI: 701, 836) cases prevented. By contrast, switching from GO to GN 160 vaccination, under 60% coverage, led to a moderate gain of impact in the undisrupted cohorts from 161 562 (UI: 444, 676) to 647 (UI: 539, 746) cases prevented, but a substantial increase in resilience 162 from 107 (UI: 7, 214) to 302 (UI: 170, 437) cases prevented per 100,000 girls born. Finally, GN 163 vaccination with 90% coverage led to the highest impact of 807 (UI: 752, 853) cases prevented 164 per 100,000 girls born in the undisrupted cohorts as well as the highest resilience of 464 (UI: 328, 165 602) cases prevented per 100,000 girls born in the disrupted cohorts.

166 Considering the required number of vaccine doses, we found a trade-off between dose-167 efficiency and resilience. In general, GO vaccination favoured dose-efficiency and GN vaccination 168 favoured resilience (Figure 1). For instance, increasing GO coverage from 60% to 90% would lead 169 to a higher impact in undisrupted cohorts, while needing less additional vaccine doses than 170 switching from GO to GN vaccination under 60% coverage. However, this switch from GO to GN 171 vaccination would yield a higher gain in resilience than when increasing GO coverage from 60% 172 to 90% (2.8-fold versus 2-fold increase). Similarly, switching from GO to GN vaccination under 173 90% coverage would require an additional doubling of the number of doses and only marginally 174 improve the impact in the undisrupted cohorts, but would produce a 2.2-fold gain in resilience.

The same trade-off between dose-efficiency and resilience was found when stratifying by Indian state. Interestingly, in the states with high cervical cancer incidence, we found slightly lower resilience under the GO strategy and a slightly greater relative gain in resilience when switching from GO to GN vaccination than in states with low incidence (supplementary Table B1, supplementary Figures B1-3). In the base case, for example, the resilience ratio for switching from GO to GN strategy (under 60% coverage) was 3-fold in states with high cervical cancer incidence and 2.7-fold in states with low cervical cancer incidence.

Sensitivity analyses on less strong disruption in vaccination coverage or alternative durations of disruption also yielded higher resilience with GN than GO vaccination (Table 1, supplementary Figures B2-3). The gain in resilience by switching from GO to GN vaccination was most evident under complete disruption of vaccination (i.e., 0% coverage at disruption) but still consistently found under less strong disruption (i.e., 20% or 40% coverage at disruption) (Table 1 part II, supplementary Figure B2). As expected, resilience decreased with longer duration of disruption, with any vaccination strategy, but was always higher with the GN strategy (Figure 2). The gain in resilience by switching from GO to GN vaccination was consistently above 2.7-fold under 60% coverage and above 2.0-fold under 90% coverage (Table 1 part III). Finally, in the scenario with no restart of vaccination, GN vaccination could ensure some resilience of at least 125 cases prevented per 100,000 girls born for eight birth cohorts from the start of disruption (Figure 2).

194

# 195 Gender-neutral vaccination to enhance progress towards elimination of cervical cancer

196 Subsequently, we assessed the feasibility of reaching the WHO elimination threshold for 197 ASIR of cervical cancer under highlighted scenarios. Introducing GO vaccination with 60% 198 coverage would have the lowest impact, reducing the nationwide ASIR of cervical cancer from 11 199 cases before the introduction of vaccination to 4.7 (UI: 4.3, 5.1) cases per 100,000 woman-years 200 in 100 years, but this remained above the WHO elimination threshold (Figure 3). The other 201 highlighted scenarios enabled elimination to be reached within 55 to 62 years. Introducing GN 202 vaccination with 60% coverage in both girls and boys would reduce incidence down to 2.8 (UI: 203 2.5, 3.2) cases per 100,000 woman-years, hence below the elimination threshold. The GO strategy 204 with 90% coverage, as recommended by WHO, would also decrease incidence below the threshold 205 to 2.4 (UI: 2.3, 2.6) cases per 100,000 woman-years. Lastly, given the already high vaccination 206 coverage of 90% in girls, switching to the GN strategy would only marginally reduce incidence to 207 2.3 (UI: 2.2, 2.3) cases per 100,000 woman-years.

Other combinations of coverage in boys and girls would also allow elimination. Without vaccination in boys, the WHO elimination threshold could be reached through a critical GO coverage of 70% (UI: 65, 73) (Figure 4). With vaccination in boys, a lower critical coverage in girls might be sufficient for elimination. For instance, coverage between 50% and 70% in girls
might also be sufficient for elimination when combined with moderate coverage (30%) in boys.

Finally, while disruption of vaccination does not prevent countries from reaching the elimination threshold eventually (provided vaccination resumes after disruption), it can prolong the number of years taken to attain this goal (supplementary Figure B4). Under the GO strategy with 90% coverage, for instance, disruption of vaccination for 5 years (as in the base case) would delay reaching elimination from 57 to 65 years since the start of vaccination. By switching to GN strategy (under 90% coverage), elimination could be reached in 58 years since the start of vaccination, even with disruption.

220

#### 221 **DISCUSSION**

222 As observed worldwide during the COVID-19 pandemic, public health programmes can 223 be dramatically impacted by the occurrence of sudden societal and infrastructural crises (WHO, 224 2021). The repercussions of disruption of healthcare systems may subsequently translate into 225 increased morbidity and mortality (Sharpless, 2020), and economic burden (Richards et al., 2020), 226 at a population-level. In the present paper, using India as an example, we illustrate how the 227 introduction of GN HPV vaccination could mitigate the negative impact of a sudden HPV vaccine 228 delivery disruption. More specifically, using a validated agent-based model, calibrated to context-229 specific data, we have simulated a range of plausible scenarios of disruption of a national HPV 230 vaccination programme and assessed the gain in resilience by shifting from GO to GN vaccination 231 in terms of the number of cervical cancer cases still prevented in the birth cohort with vaccination 232 disruption.

233 Our model-based exercise showed that in the case of HPV vaccination disruption for 5 234 years (base case), resilience increased by 2.8-fold (from 107 to 302 cases per 100,000 girls born) 235 and 2.2-fold (from 209 to 464 cases per 100,000 girls born) when shifting from GO to GN 236 vaccination under 60% and 90% coverage, respectively. GN vaccination was shown to improve 237 resilience irrespective of the duration of disruption. However, the absolute magnitude of resilience 238 and of resilience gain resulting from adding boys to routine vaccination of girls steadily decreased 239 with increasing duration of disruption, under all the vaccination strategies assessed, indicating that 240 measures to restore HPV vaccination should be implemented as soon as feasible.

The main determinant underlying the gain in resilience by switching from GO to GN vaccination is the age difference between sexual partners, with men being on average older than women within sexual partnerships almost everywhere worldwide (Wellings et al., 2006). In cases of vaccination disruption, the birth cohorts of boys vaccinated before the disruption would indirectly protect the cohorts of younger girls who missed out on vaccination during the disruption period. Since sexual behaviour is regulated by population-specific social norms, the magnitude of the resilience attributable to GN HPV vaccination is also expected to be different across populations. In India, for example, the age difference between male and female partners is on average 7 years (USAID, 2017), similar to the number of birth cohorts still retaining some protection by GN vaccination when we simulated no restart of vaccination after disruption.

251 In the present paper, we have also illustrated how the introduction of GN vaccination across 252 India would enhance progress towards the elimination of cervical cancer. In principle, elimination 253 across India could be reached with a critical level of GO coverage of 70%, which falls between 254 the average coverage observed among girls aged 9 to 15 years living in countries with an active 255 HPV vaccination programme, i.e., 53% (Bruni et al., 2021), and the coverage recommended by 256 the WHO, i.e., 90% (WHO, 2020b). On the other hand, our model-based estimates suggest that 257 cervical cancer elimination could be reached with 50% to 70% coverage in girls when combined 258 with moderate coverage in boys, even if coverage in boys were lower than that of girls. In cases 259 where GO coverage is already above 70%, GN vaccination would allow even more ambitious 260 cervical cancer control targets to be reached, which might eventually make cervical screening 261 targeted to vaccinated birth cohorts redundant (Tota, Isidean, & Franco, 2020). Moreover, as previously reported (Man, Georges, de Carvalho, et al., 2022), reaching elimination might be 262 263 challenging in the Indian states with the highest baseline cervical cancer incidence before 264 vaccination. In these cases, additional measures such as GN vaccination would be even more 265 relevant.

A limitation of our study is that the critical levels of HPV vaccination coverage found for 266 267 India are not necessarily generalisable to other populations. Baseline cervical cancer incidence and 268 the magnitude of herd effect, i.e., the indirect protection offered by the vaccinated to the 269 unvaccinated individuals of a population against HPV infection (Malagón, Laurie, & Franco, 270 2018) should be considered. These are, in turn, governed by local sexual behaviour (Bosch et al., 271 1994; Schulte-Frohlinde, Georges, Clifford, & Baussano, 2021). As mentioned above for 272 resilience, the critical level of vaccination coverage to reach cervical cancer elimination will be 273 context-specific (Baussano, Lazzarato, Ronco, & Franceschi, 2018; Lehtinen, Gray, Louvanto, & 274 Vänskä, 2022). Extrapolation of the results of this study to other populations will be limited to 275 those sharing a similar set of local social norms to India. Nevertheless, we expect the principle of 276 improving the resilience of cervical cancer prevention through a shift to GN vaccination to be 277 widely applicable, and this is supported by the consistency of our results in India when stratifying 278 by state-specific cervical cancer incidence.

279 Another limitation is the finite number of scenarios considered in which disruption of a 280 health system might occur. For example, we did not explored changes in sexual behaviour in the 281 population due to disruption. However, we did account for a large variation in the duration of 282 disruption and in vaccination coverage at disruption through our sensitivity analyses. In addition, 283 we do not consider here the influence of choice of HPV vaccine, as a quadrivalent vaccine (either 284 indigenously produced or Gardasil) would be the likely choice for India due to the price advantage. 285 In cases of using a nonavalent vaccine, or a vaccine with higher levels of cross-protection, we 286 expect similar qualitative results for resilience, and elimination of cervical cancer could be 287 expected to be more easily achieved.

288 Although a formal health-economic assessment of the introduction of GN HPV vaccination 289 in India is beyond the scope of this paper, clearly adding vaccination of boys to the routine 290 coverage of girls would approximately double the required number of vaccine doses and would 291 increase the financial effort to be made by the national government. However, it has been 292 demonstrated that GN HPV vaccination schedules are economically attractive in high-income 293 tender-based settings, in particular where GO vaccine uptake is below 80% (Qendri et al., 2020). 294 GN vaccination is likely to be even more attractive in India where population-based screening 295 programmes have not yet been widely implemented. Furthermore, the actual determinants of a 296 trade-off between redundancy and efficiency of resource allocation depends on context-specific 297 planning and assessment. In our example, to achieve greater resilience, GN vaccination with 60% 298 coverage would require more doses of vaccine while leading to fewer prevented cases of cervical 299 cancer in vaccinated cohorts without interruption than GO vaccination with 90% coverage (Figure 300 2). However, extending vaccination to boys could be easier to put in place than improving coverage 301 in girls from 60% to 90% in some contexts. Finally, shifting from a two-dose to a single-dose HPV 302 vaccination schedule could also improve the affordability of GN vaccination.

303 Having clearly illustrated the merits of GN vaccination considering different aspects across 304 different settings here and in earlier studies (Chow et al., 2021; Elfstrom et al., 2016; Lehtinen et 305 al., 2022; Lehtinen et al., 2018; Qendri et al., 2020), the next step is to establish a feasible pathway 306 for implementation (de Sanjose & Bruni, 2020). In high-income countries, where affordability was 307 not an issue, most vaccination programmes were initiated with the GO strategy, often combined 308 with catch-up in girls/women, and are now increasingly shifting towards GN vaccination. In 309 resource-limited settings, once routine vaccination in girls has been implemented, countries may 310 need to make a choice between boys' vaccination or female catch-up vaccination. That choice will 311 depend on health-economic objectives, the type of health infrastructure already in place as well as 312 societal values. In addition, shortages in vaccine supply will influence decision-making in the 313 coming years until this is resolved (WHO, 2022b).

314 In conclusion, our model-based observations show that shifting from GO to GN 315 vaccination may improve the resilience of the Indian HPV vaccination programme while also 316 enhancing progress towards the elimination of cervical cancer. Our resilience estimates go beyond 317 health-care disruption due to the COVID-19 pandemic. Indeed, any societal events undermining 318 the routine activities of a healthcare system can produce a comparable effect. Over the years, 319 disease prevention programmes have been disrupted by the occurrence of pandemics (Osterholm, 320 2017; WHO, 2021), armed conflicts (Jawad et al., 2021; McGrath, 2022), economic sanctions 321 (Germani et al., 2022), or widespread vaccine hesitancy (Larson, 2020). Therefore, we argue that such societal crises, which are unpredictable but expected to occur, should be anticipated through 322 323 careful planning of disease prevention programmes.

#### 324 ACKNOWLEDGMENTS

325 This study was funded by the Bill & Melinda Gates Foundation (grant number: INV-039876). For 326 the authors identified as personnel of the International Agency for Research on Cancer or World 327 Health Organization, the authors alone are responsible for the views expressed in this article and 328 they do not necessarily represent the decisions, policy or views of the International Agency for 329 Research on Cancer or World Health Organization. The designations used and the presentation of 330 the material in this Article do not imply the expression of any opinion whatsoever on the part of 331 WHO and the IARC about the legal status of any country, territory, city, or area, or of its 332 authorities, or concerning the delimitation of its frontiers or boundaries.

333

## 334 **DISCLOSURE**

335 The authors declare nothing to disclose.

336

# 337 DATA AVAILABILITY

Data for model calibration were publicly available from sources that are listed in the supplementary
material of an earlier publication (pp 11–13, DOI: 10.1016/S1470-2045(22)00543-5). The model
code of EpiMetHeos and Atlas are available from the authors on request.

# 341 AUTHOR CONTRIBUTIONS

- 342 Supervision, Funding acquisition: IB, PB, SR
- 343 Conceptualization, Formal analysis, Writing original draft: IB, IM
- 344 Methodology, Software, Visualization: IB, IM, DG
- 345 Validation, Writing Review & Editing: IB, IM, DG, PB, SR

346

#### 347 **REFERENCES**

- 348 Basu, P., Malvi, S. G., Joshi, S., Bhatla, N., Muwonge, R., Lucas, E., ... Poli, R. (2021).
- 349 Vaccine efficacy against persistent human papillomavirus (HPV) 16/18 infection at 10
- 350 years after one, two, and three doses of quadrivalent HPV vaccine in girls in India: a
- 351 multicentre, prospective, cohort study. *The Lancet Oncology*, 22(11), 1518-1529.
- 352 doi:10.1016/S1470-2045(21)00453-8
- 353 Baussano, I., Lazzarato, F., Ronco, G., & Franceschi, S. (2018). Impacts of human
- 354 papillomavirus vaccination for different populations: A modeling study. Int J Cancer,
- 355 *143*(5), 1086-1092. doi:10.1002/ijc.31409
- 356 Bonjour, M., Charvat, H., Franco, E. L., Piñeros, M., Clifford, G. M., Bray, F., & Baussano, I.
- 357 (2021). Global estimates of expected and preventable cervical cancers among girls born
  358 between 2005 and 2014: a birth cohort analysis. *Lancet Public Health*, 6(7), e510-e521.
  359 doi:10.1016/s2468-2667(21)00046-3
- 360 Bosch, F. X., Muñoz, N., de Sanjosé, S., Guerrerro, E., Ghaffari, A. M., Kaldor, J., ... Shah, K.
- 361 V. (1994). Importance of human papillomavirus endemicity in the incidence of cervical
- 362 cancer: an extension of the hypothesis on sexual behavior. *Cancer Epidemiol Biomarkers*363 *Prev*, 3(5), 375-379.
- 364 Bruni, L., Saura-Lázaro, A., Montoliu, A., Brotons, M., Alemany, L., Diallo, M. S., ... Bloem,
- 365 P. (2021). HPV vaccination introduction worldwide and WHO and UNICEF estimates of
- 366national HPV immunization coverage 2010-2019. Prev Med, 144, 106399.
- 367 doi:10.1016/j.ypmed.2020.106399
- 368 Bruni, L., Serrano, B., Roura, E., Alemany, L., Cowan, M., Herrero, R., . . . de Sanjose, S.
- 369 (2022). Cervical cancer screening programmes and age-specific coverage estimates for

370 202 countries and territories worldwide: a review and synthetic analysis. *Lancet Glob* 

371 *Health*, 10(8), e1115-e1127. doi:10.1016/s2214-109x(22)00241-8

- 372 Canfell, K., Kim, J. J., Kulasingam, S., Berkhof, J., Barnabas, R., Bogaards, J. A., ... Jit, M.
- 373 (2019). HPV-FRAME: A consensus statement and quality framework for modelled
- evaluations of HPV-related cancer control. *Papillomavirus Res, 8*, 100184.
- doi:10.1016/j.pvr.2019.100184
- 376 Chow, E. P. F., Tabrizi, S. N., Fairley, C. K., Wigan, R., Machalek, D. A., Garland, S. M., ...
- 377 Chen, M. Y. (2021). Prevalence of human papillomavirus in young men who have sex
- 378 with men after the implementation of gender-neutral HPV vaccination: a repeated cross-
- 379 sectional study. *Lancet Infect Dis*, 21(10), 1448-1457. doi:10.1016/s1473-
- 380 3099(20)30687-3
- 381 Colón-López, V., Díaz-Miranda, O. L., Medina-Laabes, D. T., Soto-Abreu, R., Vega-Jimenez, I.,
- 382 Ortiz, A. P., & Suárez, E. L. (2021). Effect of Hurricane Maria on HPV, Tdap, and
- 383 meningococcal conjugate vaccination rates in Puerto Rico, 2015-2019. *Hum Vaccin*
- 384 Immunother, 17(12), 5623-5627. doi:10.1080/21645515.2021.2004809
- de Sanjose, S., & Bruni, L. (2020). Is It Now the Time to Plan for Global Gender-Neutral HPV
  Vaccination? *J Infect Dis*, 222(6), 888-889. doi:10.1093/infdis/jiaa103
- 387 Elfstrom, K. M., Lazzarato, F., Franceschi, S., Dillner, J., & Baussano, I. (2016). Human
- 388 Papillomavirus Vaccination of Boys and Extended Catch-up Vaccination: Effects on the
- 389
   Resilience of Programs. J Infect Dis, 213(2), 199-205. doi:10.1093/infdis/jiv368
- 390 Gallagher, K. E., Howard, N., Kabakama, S., Mounier-Jack, S., Griffiths, U. K., Feletto, M., . . .
- 391 Watson-Jones, D. (2017). Lessons learnt from human papillomavirus (HPV) vaccination

392
-----

in 45 low- and middle-income countries. PLoS ONE, 12(6), e0177773.

393 doi:10.1371/journal.pone.0177773

- 394 Germani, F., März, J. W., Clarinval, C., & Biller-Andorno, N. (2022). Economic sanctions,
- healthcare and the right to health. *BMJ Glob Health*, 7(7). doi:10.1136/bmjgh-2022009486
- Jawad, M., Hone, T., Vamos, E. P., Cetorelli, V., & Millett, C. (2021). Implications of armed
  conflict for maternal and child health: A regression analysis of data from 181 countries
  for 2000-2019. *PLoS Med, 18*(9), e1003810. doi:10.1371/journal.pmed.1003810
- 400 Joshi, S., Anantharaman, D., Muwonge, R., Bhatla, N., Panicker, G., Butt, J., ... Basu, P.
- 401 (2022). Evaluation of immune response to single dose of quadrivalent HPV vaccine at
  402 10-year post-vaccination. *Vaccine*. doi:10.1016/j.vaccine.2022.11.044
- 403 Larson, H. J. (2020). Japan's HPV vaccine crisis: act now to avert cervical cancer cases and
  404 deaths. *Lancet Public Health*, 5(4), e184-e185. doi:10.1016/s2468-2667(20)30047-5
- 405 Lehtinen, M., Gray, P., Louvanto, K., & Vänskä, S. (2022). Editorial: In 30 years, gender-neutral
- 406 vaccination eradicates oncogenic human papillomavirus (HPV) types while screening
- 407 eliminates HPV-associated cancers. *Expert Rev Vaccines*, 21(6), 735-738.
- 408 doi:10.1080/14760584.2022.2064279
- 409 Lehtinen, M., Söderlund-Strand, A., Vänskä, S., Luostarinen, T., Eriksson, T., Natunen, K., ...
- 410 Garnett, G. (2018). Impact of gender-neutral or girls-only vaccination against human
- 411 papillomavirus-Results of a community-randomized clinical trial (I). Int J Cancer,
- 412 *142*(5), 949-958. doi:10.1002/ijc.31119

- 413 Malagón, T., Laurie, C., & Franco, E. L. (2018). Human papillomavirus vaccination and the role
- 414 of herd effects in future cancer control planning: a review. *Expert Rev Vaccines*, 17(5),
- 415 395-409. doi:10.1080/14760584.2018.1471986
- 416 Man, I., Georges, D., Bonjour, M., & Baussano, I. (2022). "Footprinting" missing
- 417 epidemiological data for cervical cancer: a case study in India. *medRxiv*.
- 418 doi:10.1101/2022.06.28.22276994
- 419 Man, I., Georges, D., de Carvalho, T. M., Ray Saraswati, L., Bhandari, P., Kataria, I., ...
- 420 Baussano, I. (2022). Evidence-based impact projections of single-dose human
- 421 papillomavirus vaccination in India: a modelling study. *Lancet Oncol, 23*(11), 1419-
- 422 1429. doi:10.1016/s1470-2045(22)00543-5
- 423 McGrath, E. (2022). Emergence of Vaccine-Preventable Diseases: The Perfect Storm of

424 Hesitancy, Refusal, a Pandemic, and War. *Pediatr Ann, 51*(11), e426-e430.


425 doi:10.3928/19382359-20220913-03

- 426 Muhoza, P., Danovaro-Holliday, M. C., Diallo, M. S., Murphy, P., Sodha, S. V., Requejo, J. H.,
- 427 & Wallace, A. S. (2021). Routine Vaccination Coverage Worldwide, 2020. *MMWR*
- 428 Morb Mortal Wkly Rep, 70(43), 1495-1500. doi:10.15585/mmwr.mm7043a1
- 429 Osterholm, M. (2017). Global Health Security An Unfinished Journey. *Emerging Infectious* 430 *Diseases*, 23, S225-S227. doi:https://doi.org/10.3201/eid2313.171528
- 431 Qendri, V., Bogaards, J. A., Baussano, I., Lazzarato, F., Vänskä, S., & Berkhof, J. (2020). The
- 432 cost-effectiveness profile of sex-neutral HPV immunisation in European tender-based
- 433 settings: a model-based assessment. *Lancet Public Health*, *5*(11), e592-e603.
- 434 doi:10.1016/s2468-2667(20)30209-7

435	Richards, M., Anderson, M., Carter, P., Ebert, B. L., & Mossialos, E. (2020). The impact of the
436	COVID-19 pandemic on cancer care. Nat Cancer, 1(6), 565-567. doi:10.1038/s43018-
437	020-0074-у
438	Schulte-Frohlinde, R., Georges, D., Clifford, G. M., & Baussano, I. (2021). Predicting cohort-
439	specific cervical cancer incidence from population-based HPV prevalence surveys: a
440	worldwide study. American Journal of Epidemiology, 191(3), 402-412.
441	doi:10.1093/aje/kwab254
442	Segi, M. (1960). Cancer mortality for selected sites in 24 countries 1950-57. Sendai, Japan:
443	Department of Public Health, Tohoku University of Medicine.
444	Sharpless, N. E. (2020). COVID-19 and cancer. Science, 368(6497), 1290.
445	doi:10.1126/science.abd3377
446	The Lancet, O. (2022). Editorial: HPV vaccination in south Asia: new progress, old challenges.
447	Lancet Oncol, 23(10), 1233. doi:10.1016/s1470-2045(22)00567-8
448	Tota, J. E., Isidean, S. D., & Franco, E. L. (2020). Defining benchmarks for tolerable risk
449	thresholds in cancer screening: Impact of HPV vaccination on the future of cervical
450	cancer screening. Int J Cancer, 147(12), 3305-3312. doi:10.1002/ijc.33178
451	USAID. (2017). The Demographic and Health Surveys (DHS) NFHS-4 India by United States
452	Agency of International Development (USAID). Retrieved from
453	https://dhsprogram.com/publications/publication-fr339-dhs-final-reports.cfm
454	Wellings, K., Collumbien, M., Slaymaker, E., Singh, S., Hodges, Z., Patel, D., & Bajos, N.
455	(2006). Sexual behaviour in context: a global perspective. Lancet, 368(9548), 1706-1728.
456	doi:10.1016/s0140-6736(06)69479-8

- 457 WHO. (2020a). Coronavirus disease (COVID-19) pandemic. Retrieved from
- 458 https://www.who.int/europe/emergencies/situations/covid-19
- 459 WHO. (2020b). Global strategy to accelerate the elimination of cervical cancer as a public health
- 460 problem. Retrieved from <u>https://www.who.int/publications/i/item/9789240014107</u>
- 461 WHO. (2021). Third round of the global pulse survey on continuity of essential health services
- 462 during the COVID-19 pandemic. Retrieved from
- 463 <u>https://www.who.int/publications/i/item/WHO-2019-nCoV-EHS\_continuity-survey-</u>
- 464 <u>2022.1</u>
- 465 WHO. (2022a). Global Vaccine Market Report 2022. Retrieved from
- 466 https://www.who.int/publications/m/item/global-vaccine-market-report-2022
- 467 WHO. (2022b). WHO HPV Vaccine Global Market Study. Retrieved from
- 468 <u>https://www.who.int/publications/m/item/who-hpv-vaccine-global-market-study-april-</u>
- 469 <u>2022</u>
- 470

## 471 FIGURES



473 Figure 1. Resilience against HPV vaccination disruption in the base case. Predicted


474 resilience, defined as life-time number of cervical cancer cases still prevented in the birth cohorts


475 with disruption of vaccination per 100,000 girls born (blue arrow), and drop in cervical cancers

476 prevented as compared to impact in the cohorts vaccinated prior to the disruption (black arrow),


477 under the four highlighted scenarios. Disruption was simulated according to the base case with a

478 period of disruption of 5 years and 0% coverage in girls and boys during the disruption period.













Figure 3. Progress towards cervical cancer elimination over time. Predicted cervical cancer age-standardised incidence (in cases per 100,000 woman-years) in the years since start of vaccination in India under no vaccination and in the four highlighted scenarios. The dashed line represents the WHO elimination threshold for cervical cancer elimination as a public health priority, i.e., age-standardised incidence of 4 cases per 100,000 woman-years. Disruption was simulated according to the base case with a period of disruption of 5 years and 0% coverage in girls and boys during the disruption period.





497 Figure 4. Attainment of cervical cancer elimination in the long term. Heatmap of the predicted 498 cervical cancer age-standardised incidence rate (in cases per 100,000 woman-years) in the long-499 term (i.e., at 100 years after the start of vaccination) in India by vaccination coverage in girls and 500 boys (under no disruption of vaccination). The dashed curve represents the WHO elimination 501 threshold for cervical cancer elimination, i.e., age-standardised incidence of 4 cases per 100,000 502 woman-years. The five black circles correspond to no vaccination and the four highlighted 503 scenarios: girls-only strategy with 60% coverage, girls-only strategy with 90% coverage, gender-504 neutral strategy with 60% coverage, and gender-neutral strategy with 90% coverage. The 505 horizontal arrows represent scale-up of vaccination by increasing coverage in girls, and the vertical 506 arrows represent switching to gender-neutral vaccination.

## 507 TABLES

508 Table 1. Sensitivity analyses on coverage at disruption and duration of disruption on resilience. Life-time number of cervical

509 cancer cases prevented per 100,000 girls born in birth cohorts vaccinated prior to disruption in part I. Sensitivity analyses on coverage

510 at disruption in part II and on duration of disruption in part III on resilience (defined as the life-time number of cervical cancer cases

- 511 still prevented in the birth cohorts with disruption of vaccination per 100,000 girls born) and resilience ratio (defined as fold change in
- 512 resilience by switching from one scenario to another). Uncertainty intervals are reported in brackets.

I. Life-time number of cervical cancer cases prevented prior to disruption

Scenario	GO 60%	GO 90%	GN 60%	GN 90%
No disruption	562 (444, 676)	773 (701, 836)	647 (539, 746)	807 (752, 853)

II. Sensitivity analyses on coverage at disruption (with duration of disruption fixed at 5 years)

Coverage at	Resilie	Resilience by vaccination strategy and coverage			Resilience ratio		
Coverage at disruption in %	GO 60% GO 90%	CO 00%	0% GN 60%	GN 90%	GO 60% to	GO 60% to	GO 90% to
distuption in 76		GIN 0070	UN 90%	GO 90%	GN 60%	GN 90%	
0 (base case)	107 (7, 214)	209 (81, 340)	302 (170, 437)	464 (328, 602)	2.0	2.8	2.2
20	271 (155, 391)	355 (221, 490)	425 (297, 559)	550 (416, 680)	1.3	1.6	1.6
40	410 (277, 534)	476 (343, 599)	527 (401, 647)	621 (500, 730)	1.2	1.3	1.3

III. Sensitivity analyses on duration of disruption (with coverage at disruption fixed at 0%)

Duration of	Resilience by vaccination strategy and coverage			Resilience ratio			
disruption in years	GO 60% GO 90%	CO 000/	GN 60%	GN 90%	GO 60% to	GO 60% to	GO 90% to
disruption in years		GN 00%	GIN 90%	GO 90%	GN 60%	GN 90%	
1	137 (26, 253)	261 (125, 407)	365 (215, 502)	517 (372, 655)	1.9	2.7	2.0
2	125 (17, 233)	240 (105, 375)	344 (206, 480)	500 (359, 642)	1.9	2.7	2.1
5 (base case)	107 (7, 214)	209 (81, 340)	302 (170, 437)	464 (328, 602)	2.0	2.8	2.2
10	80 (0, 182)	154 (33, 275)	226 (96, 358)	382 (240, 525)	1.9	2.8	2.5